Wedbush takes a shine to Idenix Pharmaceuticals (IDIX +3.5%), ringing up an upgrade to...


Wedbush takes a shine to Idenix Pharmaceuticals (IDIX +3.5%), ringing up an upgrade to Outperform from Neutral to go along with a $5 price target hike to $11. Analysts with the firm tie the new rating to the "heightened premium" they see big-pharma placing on the nucleotide class of drugs following positive data released on Pharmasset’s (VRUS +2.3%) PSI-7977 treatment.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs